Xiaoqing Boynton is a Partner in the China practice at Albright Stonebridge Group (ASG), part of DGA Group. She brings nearly 20 years of experience working on U.S.-China issues to help clients navigate commercial and policy issues regarding the Chinese market, specializing in market entry and expansion, risk management, and government relations.

Most recently, Ms. Boynton served as Senior Director for International Affairs at the Biotechnology Innovation Organization (BIO), the world’s largest biotech association. There, she was responsible for developing and executing BIO’s advocacy strategy in key Asian markets, with a focus on China and Japan. As BIO’s lead on Asia policy issues, she worked closely with BIO board and member companies to support the development of next-generation biotech solutions and create an ecosystem for innovation.

Previously, Ms. Boynton was a Vice President in ASG’s China practice. Before that, she served as a Fellow at the Center for Strategic and International Studies, where she led projects on Chinese socioeconomic transformation and global health issues. She also consulted for Eurasia Group and Global Health Strategies on health security and pharmaceutical industry projects in Asia. Early in her career, she worked at the American Bar Association’s Asia Law Initiative in Beijing.

Ms. Boynton has been interviewed on U.S.-China and health care issues by news outlets including The Wall Street Journal, Bloomberg, NPR, and the South China Morning Post, and has testified before the U.S.-China Economic and Security Review Commission.

Ms. Boynton holds an M.A. in International Development from Brandeis University and a B.A. in International Economics and Trade from Beijing Second Foreign Language University. She is fluent in Mandarin Chinese.

She is based in Washington, D.C.